Is Inspire Medical Systems (INSP) Fully Priced As New CPT Codes Lift Sentiment?
Alpha Vantage · Simply Wall Street · · AI-summarised by FinFlash
Inspire Medical Systems (INSP) gained investor attention after new Category I CPT codes for its Inspire V system were approved, set to take effect in January 2028. Despite recent share price momentum, the stock has experienced significant long-term declines. Analysts present a mixed valuation, with the most followed narrative suggesting INSP is 16% overvalued against a fair value of $60.40, while its current P/E ratio of 15x suggests it might be cheaper than peers and its own fair ratio.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.